BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy

BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy

Bristol Myers Squibb is paying $50 million to begin a collaboration with Janux Therapeutics, a company that develops T cell engagers that activate specifically at the site of the tumor. It’s the second big pharma alliance for Janux, which has been working with Merck. The post BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy appeared first on MedCity News.

Bristol Myers buys into Janux’s ‘masked’ T cell engagers

Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote.

BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy – RamaOnHealthcare

Bristol Myers Squibb is paying $50 million to begin a collaboration with Janux Therapeutics, a company that develops T cell engagers that activate

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Janux Therapeutics, Inc. (NASDAQ:JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE:BMY). San Diego-based Janux will receive up to $50 million in upfront and near-term milestone payments, with potential total payments reaching…

Bristol Myers signs deal with Janux on T cell engager for $50M upfront

Janux Therapeutics has found a new partner. The San Diego-based biotech is teaming up with Bristol Myers Squibb on a solid tumor program, but the target is not yet disclosed. Bristol ...